Burcon announces GRAS status for Puratein(R) & Sup... ( VANCOUVER Oct. 7 / Burcon NutraSc...)

Burcon announces GRAS status for Puratein(R) & Supertein(TM)

Date:10/7/2008

VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - Burcon NutraScience Corporation (TSX-V: BU) announced today that its Puratein(R) and Supertein(TM) canola protein isolates are GRAS (Generally Recognized As Safe) for their intended use in a variety of food and beverage applications. The products have been self-affirmed GRAS through an independent evaluation by a panel of qualified experts in the fields of food safety, toxicology, nutritional sciences, food allergies and pediatric nutrition. Burcon's Puratein(R) and Supertein(TM) are the first canola protein isolates to have attained GRAS status in the United States. GRAS status permits Puratein(R) and Supertein(TM) to be marketed and used in a variety of mainstream foods and beverages for human consumption.

Puratein(R) and Supertein(TM) are expected to participate with soy, dairy and egg proteins in the multi-billion dollar global protein ingredient market. Protein ingredients are valued for both their nutritional qualities as well as their functional applications in foods and beverages.

Puratein(R) is a canola protein isolate with functional properties that include emulsification, gel formation, thickening, formation of heat-stable foams, and water- and ingredient-binding. Applications for Puratein(R) include dressings, meat substitutes, baked goods and protein bars, among many others.

Supertein(TM) is a canola protein isolate with functional properties including excellent solubility, the ability to form transparent solutions and foaming. Applications for Supertein(TM) include beverages, confectionery, aerated desserts, and protein bars, among many others. Nutritionally, the proteins are equally exciting with unique amino acid profiles.

"Achieving GRAS status is a major advancement in the commercialization of Puratein(R) and Supertein(TM), the world's first food-grade canola proteins," stated Johann F. Tergesen, Burcon's President & COO who added, "We benefited from the expertise of our
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine technology :

1. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
2. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
3. Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
9. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
10. Evalve Announces Enrollment Completion of the EVEREST Randomized Study
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)

Post Your Comments:

Burcon announces GRAS status for Puratein(R) & Sup...( VANCOUVER Oct. 7 / Burcon NutraSc...),Health